F-1: Psyence Biomedical Files for Resale of 22.5 Million Shares Following Business Combination

Psyence Biomedical Ltd. has filed a registration statement for the resale of approximately 22.5 million common shares by selling shareholders after its recent business combination.

Summary

• Psyence Biomedical Ltd. has filed a registration statement for the resale of 22,496,000 common shares.
• The shares are to be sold by various selling shareholders, including investors from a recent financing, advisors who received shares in lieu of fees, and the sponsor of the SPAC involved in the business combination.
• The company will not receive any proceeds from the sale of these shares.
• The filing details the background of the business combination, including the securities purchase agreement and related agreements.
• Psyence Biomedical is a life science biotechnology company focused on developing natural psilocybin medicinal formulations and treatment protocols for adjustment disorder in patients with an incurable cancer diagnosis.
• The company's lead product candidate is PEX010, a capsule containing 25mg naturally sourced psilocybin, currently in a Phase IIb study.
• The company has contracted iNGEN Pty Ltd to conduct a Phase IIb double-blind, randomized, low-dose controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder (AjD) due to incurable cancer.
• The 84-patient Phase IIb Study is in the late planning stage, and estimated to commence enrollment in H1Q4 2024.
• The initial Conversion Price of the First Tranche Notes was $10.00; provided, however, that such Conversion Price is subject to certain adjustments according to the terms and reset dates included in the First Tranche Notes and may be reduced to a Conversion Floor of $1.00, until the First Reset Date (as such term is defined in the First Tranche Notes), then to $0.50 on the Second Reset Date (as such term is defined in the First Tranche Notes) and to $0 thereafter.

Sentiment

Score: 5

Explanation: The document is a regulatory filing, so the sentiment is neutral. It contains both positive aspects (clinical trials, potential market) and negative aspects (losses, risks).

Positives

• The company's lead product candidate, PEX010, has received regulatory approval to proceed into Phase I and II clinical trials in several jurisdictions worldwide.
• PEX010 is also being administered to real-world patients via the Health Canada Special Access Program (SAP), with no serious adverse events reported.
• The company's CEO and Medical Director have extensive experience in the pharmaceutical industry related to R&D and commercialization of new products.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling shareholders.
• The company has incurred losses in each year since its inception and expects to incur significant losses for the foreseeable future.
• The company is dependent on licensed intellectual property and could lose rights if agreements are breached.
• The market price and trading volume of the Common Shares may be volatile and could decline significantly following the Business Combination.

Risks

• The company is a clinical-stage biotechnology company and has incurred significant losses since its inception.
• The company will require substantial additional funding to achieve its business goals.
• The psychedelic therapy and biotechnology industries are undergoing rapid growth and substantial change, which has resulted in an increase in competitors.
• Current and future preclinical and clinical studies will be conducted outside the United States, and the FDA may not accept data from such studies.
• There is a high rate of failure for product candidates proceeding through clinical trials.
• The company is dependent on licensed intellectual property.
• The company may not be able to adequately protect or enforce its intellectual property rights.
• The market price and trading volume of the Common Shares may be volatile and could decline significantly following the Business Combination.

Future Outlook

The company plans to expand their targeted indication of cancer-related AjD to address different types of AjD and other secondary indications both in a palliative and non-palliative context.

Industry Context

The document notes that there are currently no pharmaceutical agents with regulatory approval for the treatment of AjD within palliative care or any other arena, suggesting a potential first-mover advantage for Psyence.

Comparison to Industry Standards

• The document references Compass Pathways' clinical trial, highlighting the common occurrence of suicidal ideation and intentional self-injury in TRD studies, which is a relevant benchmark for assessing the risks associated with Psyence's clinical trials.

Related Party Transactions

• On January 25, 2024, the Company issued an unsecured convertible promissory note to Parent (the PGI Note), in the principal amount of $1,610,657.
• On January 25, 2024, NCAC issued an unsecured convertible promissory note to the Sponsor (the NCAC Replacement Note), in the principal amount of $1,615,501.

Stakeholder Impact

• Shareholders may experience dilution due to the potential conversion of notes and exercise of warrants.
• The company's success could positively impact patients with adjustment disorder and their families.
• The company's operations could create jobs and economic opportunities in the regions where it operates.

Next Steps

• Commence enrollment in the Phase IIb Study in H1Q4 2024.
• Potentially proceed to a Phase III trial in the United States, subject to FDA review and the opening of an IND.
• File a registration statement covering the resale of the Common Shares issuable upon conversion of the First Tranche Notes.

Key Dates

Keywords

Psyence Biomedical, PEX010, Business Combination, Common Shares, Psilocybin, Clinical Trial, Adjustment Disorder, Selling Shareholders, Financing, Biotechnology